The Platform launches in 2026 with the collaboration layer. Projects, experiments, team access. That’s enough for most teams that outgrew file shares.
But some teams need more. Pharma, biotech, regulated environments, large core facilities. They have specific needs around pipelines, security, and deployment that we’re explicitly not solving in the launch product. That’s deliberate. Ship one thing well, then add what’s earned.
Here’s what 2027 looks like for those teams.
Pipeline integration
Today, segmentation and analysis run through the Analysis tool, a separate Docker container with its own UI. That’s great for hands-on work. But teams running thousands of plates a week need to kick off jobs from the Platform itself, watch progress, and get results back where the team is already working.
In 2027, the Platform gets first-class pipelines. You’ll be able to:
- Configure a pipeline once, run it across an entire experiment
- Schedule recurring runs (overnight processing, weekly batches)
- Watch progress in real time, get notified when it’s done
- See results in the same view as the raw data
The Analysis tool stays. It’s still the right surface for tuning a pipeline. But once it’s tuned, the Platform runs it at scale.
Enterprise-ready features
This is the boring-but-essential category. The features that take a year to build, that nobody talks about at conferences, but that pharma procurement asks about on call number one.
In 2027:
- SSO via SAML, OIDC, and Microsoft Entra ID. Your IT team configures it, your scientists log in with their corporate credentials.
- Audit logs. Every action attributed, timestamped, exportable. Regulated environments need this. We give it to everyone.
- Role-based access control. Beyond the launch sharing model. Custom roles, scoped permissions, fine-grained policies.
- GDPR and HIPAA alignment. Specific deployment configurations and contracts that meet regulated-environment requirements.
None of this is interesting to look at. All of it is required to do business with pharma at scale.
Procurement through AWS Marketplace
Pharma and biotech R&D teams often have AWS Enterprise Discount Program commitments [1]. Buying through AWS Marketplace counts against those commitments. No new vendor onboarding. No separate procurement process. Days, not months.
In 2027 we list the Platform as a SaaS product on AWS Marketplace. Your AWS account becomes your Find Nuclei account. The same enterprise tier, just zero procurement friction.
Runs where you need it
Three deployment modes in 2027:
- Managed SaaS. What most teams want. We run it, you use it. Fast onboarding, no infrastructure work.
- Self-hosted. You run the Platform inside your own infrastructure. Same code, different deployment. For teams with strict data residency or air-gap requirements.
- Bring-your-own-cloud. The hybrid. We run the control plane, your data plane stays in your AWS account. The compromise that pharma actually wants: minimal vendor risk, minimal ops burden.
What we’re explicitly not doing in 2027
A few things we’ve considered and decided no on, for clarity:
- A wet-lab LIMS replacement. Stay focused on imaging.
- A Benchling competitor. Same reason. We integrate, we don’t replace.
- An on-premise installer with a generic database. Postgres only.
- Custom contract negotiations under $100K per year. AWS Marketplace handles smaller enterprise deals.
Rough timeline
Concrete dates come closer to delivery, but the 2027 plan is roughly:
- Q1 2027: AWS Marketplace listing live. Audit logs. SAML SSO.
- Q2 2027: Pipeline integration v1.
- Q3 2027: Self-hosted deployment available.
- Q4 2027: Bring-your-own-cloud option for enterprise.
If your team needs something specific from this list earlier, get in touch. We pick first customers carefully and partner closely on roadmap. Join the Platform waitlist and tell us what you need.
References
[1] AWS Enterprise Discount Program (EDP). AWS Marketplace. https://aws.amazon.com/marketplace/features/enterprise-discount-program